Overall survival by genetic abnormalities. (A) Overall survival is indicated in the 10 patients with HOX11L2⁺ (bold dotted line) and the 11 patients with SIL-TAL1⁺ T-ALL (thin dotted line) compared with the 60 other patients tested (solid line). Survival was significantly worse in the HOX11L2⁺ subset (11% at 4 years; P = .003 by the log-rank test), but not in the SIL-TAL1⁺ subset (45% at 4 years; P = .67 by the log-rank test), compared with other patients (47% at 4 years). (B) HOX11 expression. Overall survival is indicated in the 11 patients with HOX11⁺ (dotted line) compared with the 70 other patients tested (solid line). No significant difference was observed between these 2 subsets (P = .21 by the log-rank test).